On Sept. 10, HSBC analyst Rajesh Kumar maintained his "buy" rating on AbbVie ( ABBV +0.53%), raising his price target on the ...

AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and ...

AbbVie already shared last month that its Skyrizi had trounced Johnson & Johnson’s rival biologic drug Stelara in Crohn’s disease. Now, detailed trial results show just how decisive Skyrizi’s win is.

AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.

Skyrizi and Rinvoq are cornerstones in AbbVie’s post-Humira battle plan. Together, the drugmaker expects the meds to reap a combined $15 billion in sales in 2025. (AbbVie) AbbVie’s immunology stalwart ...

"At AbbVie, patients are at the heart of everything we do," said Kori Wallace, M.D., Ph.D., vice president, immunology clinical development, AbbVie. "We are motivated to bring new treatment options to ...